首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | NRG1 |
| Uniprot No | Q02297 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 20-242aa |
| 氨基酸序列 | SGKKPESAAGSQSPALPPRLKEMKSQESAAGSKLVLRCETSSEYSSLRFK WFKNGNELNRKNKPQNIKIQKKPGKSELRINKASLADSGEYMCKVISKLG NDSASANITIVESNEIITGMPASTEGAYVSSESPIRISVSTEGANTSSST STSTTGTSHLVKCAEKEKTFCVNGGECFMVKDLSNPSRYLCKCQPGFTGA RCTENVPMKVQNQEKAEELYQKR |
| 预测分子量 | 24 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于NRG1重组蛋白的3篇参考文献的简要概括：
---
1. **文献名称**：*Neuregulin-1 protects ventricular myocytes from anthracycline-induced apoptosis via ErbB4-dependent modulation of oxidative stress*
**作者**：Bian et al.
**摘要**：该研究探讨了重组NRG1蛋白通过激活ErbB4受体，抑制阿霉素诱导的心肌细胞氧化应激和凋亡的机制，表明其在化疗相关心脏毒性中的保护作用。
---
2. **文献名称**：*Recombinant neuregulin-1 stabilizes endothelial cell function and reduces inflammation in sepsis models*
**作者**：Gao et al.
**摘要**：研究利用重组NRG1蛋白处理脓毒症模型中的内皮细胞，发现其通过PI3K/Akt信号通路增强内皮屏障功能并减少炎症因子释放，提示其潜在治疗价值。
---
3. **文献名称**：*Structural and functional characterization of a novel NRG1 isoform expressed in the central nervous system*
**作者**：Chen et al.
**摘要**：该文献报道了一种新型中枢神经系统特异性NRG1重组蛋白的克隆与功能分析，揭示其通过调节神经元突触可塑性影响认知功能的分子机制。
---
这些文献覆盖了NRG1重组蛋白在心脏保护、炎症调控及神经科学中的关键研究。如需更多领域的研究，可进一步补充。
Neuregulin-1 (NRG1) is a member of the epidermal growth factor (EGF) family of signaling proteins, playing critical roles in cellular communication, development, and tissue homeostasis. Originally identified for its involvement in Schwann cell and neuronal development, NRG1 has since been recognized as a multifunctional regulator across diverse biological systems. It exists in multiple isoforms generated by alternative splicing, with the most studied variants categorized into types I, II, III, and IV. These isoforms differ in their N-terminal sequences and membrane-binding domains, enabling tissue-specific signaling through interactions with ErbB receptor tyrosine kinases (primarily ErbB3 and ErbB4).
Recombinant NRG1 protein is engineered using biotechnological methods, typically in mammalian or bacterial expression systems, to produce bioactive fragments mimicking the native EGF-like domain. This domain is essential for receptor binding and activation, triggering downstream pathways such as PI3K-AKT, MAPK/ERK, and JAK-STAT, which influence cell proliferation, differentiation, and survival. In research, recombinant NRG1 has been instrumental in elucidating its roles in cardiac development, neuronal plasticity, and mammary gland morphogenesis. Notably, NRG1-ErbB signaling is vital for maintaining cardiomyocyte function and has therapeutic potential in heart failure.
Clinically, recombinant NRG1 has entered trials for treating heart failure, leveraging its cardioprotective effects. It also holds promise in neurodegenerative diseases, cancer therapy (via modulation of ErbB receptors), and regenerative medicine. Challenges remain in optimizing isoform-specific activity, delivery methods, and understanding context-dependent signaling outcomes. Overall, recombinant NRG1 serves as a powerful tool for both basic research and translational applications, bridging molecular mechanisms to therapeutic innovation.
×
